Wojciech Senkowski

Wojciech Senkowski serves as an Assistant Professor at the University of Copenhagen's Biotech Research & Innovation Centre (BRIC), where he is a key member of the Wennerberg Group within the Faculty of Health and Medical Sciences. His research focuses on cancer biology with particular emphasis on ovarian cancer, drug resistance mechanisms, and the development of organoid models for personalized medicine approaches.

Dr. Senkowski's research interests span cancer biology, molecular pathways in tumor development, and precision medicine applications. His work particularly emphasizes understanding drug resistance in ovarian cancer, developing patient-derived organoid models, and identifying novel therapeutic targets through molecular pathway analysis. His research bridges basic science with clinical applications, aiming to translate findings into improved treatment strategies for cancer patients.

His recent publications demonstrate a strong focus on ovarian cancer research, with significant contributions to understanding tumor evolution, drug resistance mechanisms, and the development of organoid models for drug response profiling. His work spans from fundamental molecular biology investigations to translational research with direct clinical implications, particularly in the areas of platinum-resistant ovarian cancer and precision oncology approaches.

Dr. Senkowski actively collaborates with numerous researchers across multiple institutions, as evidenced by his co-authorship on publications in high-impact journals including Nature Communications, Science Advances, Cancer Cell, and Developmental Cell. His research has gained significant attention in the scientific community, with multiple papers receiving substantial citations and media coverage.

Based at Ole Maaløes Vej 5 in Copenhagen, Dr. Senkowski works within the Wennerberg Group, a research team focused on cancer systems biology and drug discovery. His laboratory utilizes advanced techniques including single-cell transcriptomics, 3D organoid culture systems, and high-throughput drug screening to investigate cancer biology and develop novel therapeutic approaches.